References
- Gulliver A, Griffiths KM, Mackinnon A, et al. The mental health of Australian elite athletes. J Sci Med Sport. 2015;18(3):255–261.
- Wolanin A, Hong E, Marks D, et al. Prevalence of clinically elevated depressive symptoms in college athletes and differences by gender and sport. Br J Sports Med. 2016;50:167–171.
- Joy E, Kussman A, Nattiv A. Update on eating disorders in athletes: a comprehensive narrative review with a focus on clinical assessment and management. Br J Sports Med. 2016;2016(50):154–162.
- Reardon CL, Factor RM. Sport psychiatry: a systematic review of diagnosis and medical treatment of mental illness in athletes. Sports Med. 2010;40(11):961–980.
- Baum AL. Psychopharmacology in athletes. In: Begel D, Burton RW, editors. Sport psychiatry. New York, NY: WW Norton & Company; 2000. p. 249–259.
- Watson P, Hasegawa H, Roelands B, et al. Acute dopamine/noradrenaline reuptake inhibition enhances human exercise performance in warm, but not temperate conditions. J Physiol. 2005;565.3:873–883.
- Roelands B, Hasegawa H, Watson P, et al. Performance and thermoregulatory effects of chronic bupropion administration in the heat. Eur J Appl Physiol. 2009;105(3):493–498.
- Prohibited List. World Anti-Doping Agency; 2016 [cited 2016 Apr 14]. Available from: https://www.wada-ama.org/en/resources/science-medicine/prohibited-list
- Parise G, Bosman MJ, Boecker DR. Selective serotonin reuptake inhibitors: their effect on high-intensity exercise performance. Arch Phys Med Rehabil. 2001;82:867–871.
- Meeusen R, Piacentini MF, Van Den Eynde S, et al. Exercise performance is not influenced by a 5-HT reuptake inhibitor. Int J Sports Med. 2001;22:329–336.
- Brambilla P, Cipriani A, Hotopf M, et al. Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data. Pharmacopsychiatry. 2005;38(2):69–77.
- Juliff LE, Halson SL, Peiffer JJ. Understanding sleep disturbance in athletes prior to important competitions. J Sci Med Sport. 2015;18:13–18.
- Schobersberger W, Schobersberger B. The traveling athlete: from jet leg to jet lag. Curr Sports Med Rep. 2012;11(5):222–223.
- Marvin G, Sharma A, Aston W, et al. The effects of buspirone on perceived exertion and time to fatigue in man. Exp Physiol. 1997;82:1057–1060.
- Atkinson G, Drust B, Reilly T, et al. The relevance of melatonin to sports medicine and science. Sports Med. 2003;33(11):809–831.
- Paul MA, Gray G, Kenny G, et al. Impact of melatonin, zaleplon, zopiclone, and temazepam on psychomotor performance. Aviat Space Environ Med. 2003;74(12):1263–1270.
- Holmberg G. The effects of anxiolytics on CFF. Pharmacopsychiatry. 1982;15(Suppl):49–53.
- Maddock RJ, Casson EJ, Lott LA, et al. Benzodiazepine effects on flicker sensitivity: role of stimulus frequency and size. Prog Neuropsychopharmacol Biol Psychiatry. 1993;17:955–970.
- Guidelines-therapeutic use exemptions (TUE). World Anti-Doping Agency; 2016 [cited 2016 Apr 14]. Available from: https://www.wada-ama.org/en/resources/science-medicine/guidelines-therapeutic-use-exemptions-tue
- 2015–2016 drug-testing exceptions procedures (medical exceptions). NCAA Health and Safety; 2015 [cited 2016 Apr 14]. Available from: http://www.ncaa.org/health-and-safety/sport-science-institute/2015-16-drug-testing-exceptions-procedures-medical-exceptions
- Roelands B, Hasegawa H, Watson P, et al. The effects of acute dopamine reuptake inhibition on performance. Med Sci Sports Exercise. 2008;40(5):879–885.
- Ng F, Hallam K, Lucas N, et al. The role of lamotrigine in the management of bipolar disorder. Neuropsychiatr Dis Treat. 2007;3(4):463–474.
- Beach SR, Celano CM, Noseworthy PA, et al. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics. 2013;54(1):1–13.
- Grohol J. Top 25 psychiatric medication prescriptions for 2013. Psych Central; 2015 [cited 2016 Apr 14]. Available from: http://psychcentral.com/lib/top-25-psychiatric-medication-prescriptions-for-2013
- Patel DR, Omar H, Terry M. Sport-related performance anxiety in young female athletes. J Pediatr Adolesc Gynecol. 2010;23:325–335.
- Reardon CL, Factor RM. Considerations in the use of stimulants in sport. Sports Med. 2015. [cited 2015 Dec 28]. doi:10.1007/s40279-015-0456-y.
- López FA, Leroux JR. Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges. Atten Defic Hyperact Disord. 2013;5(3):249–265.
- Morse ED. Substance use in athletes. In: Baron DA, Reardon CL, Baron SH, editors. Clinical sports psychiatry: an international perspective. Oxford: Wiley-Blackwell; 2013. p. 3–12.
- Glick ID, Morse E, Reardon CL, et al. Sport psychiatry-a new frontier in a challenging world. Die Psychiatrie. 2010;7:249–253.
- Glick ID, Newmark T, Reardon CL. Sports psychiatry: current status and challenges. In: Baron DA, Reardon CL, Baron SH, editors. Clinical sports psychiatry: an international perspective. Oxford: Wiley-Blackwell; 2013. p. 215–218.